Maleat De Ergometrină Zentiva

Ergometrine maleate, the active ingredient in Maleat De Ergometrină Zentiva, is an ergot alkaloid presented as an injectable solution for intramuscular or intravenous use. It treats postpartum hemorrhage and uterine atony in obstetric patients.

GNH USA supplies Maleat De Ergometrină Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Ergometrine maleate is used in obstetrics to promote uterine contraction and control bleeding.

- Postpartum hemorrhage: helps control excessive bleeding after delivery by stimulating sustained uterine contraction. - Uterine atony: restores tone in a relaxed uterus to reduce the risk of ongoing blood loss. - Induction of labor (in selected protocols): facilitates cervical ripening and uterine activity when medically indicated.

Ergometrine maleate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Headache - Transient hypertension - Flushing - Abdominal discomfort - Vomiting

Serious or Rare Side Effects: - Severe hypertension or hypertensive crisis - Coronary artery spasm - Pulmonary edema - Thromboembolic events - Anaphylactic or severe allergic reaction - Ischemic necrosis of extremities

Ergometrine maleate requires careful clinical monitoring before and after administration.

- Cardiovascular assessment: monitor blood pressure and heart rate closely. - Uterine tone evaluation: ensure indication of uterine atony or hemorrhage. - Contraindication in uncontrolled hypertension: avoid unless benefits outweigh risks. - Review concomitant vasoconstrictive agents: assess for additive effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ergometrine maleate can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Ergot‑derived vasoconstrictors (e.g., ergotamine) – additive vasoconstriction. - Monoamine oxidase inhibitors – risk of hypertensive crisis. - Potent alpha‑adrenergic blockers – may blunt therapeutic uterine contraction.

Moderate Interactions (Monitor Closely): - Beta‑blockers – may alter cardiovascular response. - Calcium channel blockers – possible attenuation of uterine tone. - Selective serotonin reuptake inhibitors – potential serotonergic effects.